Value Health. 2009 May 15. [Epub ahead of print]
Cost Utility of Sequential Adjuvant Trastuzumab for HER2/Neu-Positive Breast Cancer.
Reed SD, Schulman KA.
Center for Clinical and Genetic Economics, Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA;
PMID: 19473336 [PubMed - as supplied by publisher]